Drug General Information |
Drug ID |
D0W2BK
|
Former ID |
DCL001059
|
Drug Name |
ICo-007
|
Drug Type |
Antisense drug
|
Indication |
Diabetic macular edema; Diabetic retinopathy [ICD9: 250, 250.5, 362.0-362.2, 362.01, 362.07, 362.53, 782.3; ICD10:E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35-H35.2, H35.8, H36]
|
Phase 1 |
[1]
|
Therapeutic Class |
Antisense
|
Company |
ISIS Pharm; iCo Therapeutics
|
Target and Pathway |
Target(s) |
mRNA of RAF proto-oncogene serine/threonine-protein kinase |
Target Info |
|
[2],
[1],
[3]
|
BioCyc Pathway
|
MAP kinase cascade
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
FoxO signaling pathway
|
Sphingolipid signaling pathway
|
PI3K-Akt signaling pathway
|
Vascular smooth muscle contraction
|
VEGF signaling pathway
|
Focal adhesion
|
Gap junction
|
Signaling pathways regulating pluripotency of stem cells
|
Natural killer cell mediated cytotoxicity
|
T cell receptor signaling pathway
|
B cell receptor signaling pathway
|
Fc epsilon RI signaling pathway
|
Fc gamma R-mediated phagocytosis
|
Long-term potentiation
|
Neurotrophin signaling pathway
|
Serotonergic synapse
|
Long-term depression
|
Regulation of actin cytoskeleton
|
Insulin signaling pathway
|
GnRH signaling pathway
|
Progesterone-mediated oocyte maturation
|
Estrogen signaling pathway
|
Melanogenesis
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Oxytocin signaling pathway
|
Alcoholism
|
Tuberculosis
|
Hepatitis C
|
Hepatitis B
|
Influenza A
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Colorectal cancer
|
Renal cell carcinoma
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Bladder cancer
|
Chronic myeloid leukemia
|
Acute myeloid leukemia
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
IL5 Signaling Pathway
|
IL2 Signaling Pathway
|
EGFR1 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
B cell activation
|
EGF receptor signaling pathway
|
Endothelin signaling pathway
|
FGF signaling pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
Integrin signalling pathway
|
Interleukin signaling pathway
|
PDGF signaling pathway
|
T cell activation
|
VEGF signaling pathway
|
Ras Pathway
|
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
|
CCKR signaling map ST
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
Endothelins
|
BCR signaling pathway
|
GMCSF-mediated signaling events
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
CDC42 signaling events
|
SHP2 signaling
|
mTOR signaling pathway
|
IL2-mediated signaling events
|
IGF1 pathway
|
Ras signaling in the CD4+ TCR pathway
|
Ceramide signaling pathway
|
ErbB1 downstream signaling
|
ErbB2/ErbB3 signaling events
|
PDGFR-beta signaling pathway
|
p38 signaling mediated by MAPKAP kinases
|
Nongenotropic Androgen signaling
|
Internalization of ErbB1
|
CXCR3-mediated signaling events
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Class I PI3K signaling events mediated by Akt
|
Trk receptor signaling mediated by the MAPK pathway
|
Downstream signaling in naï
|
Regulation of retinoblastoma protein
|
Signaling events mediated by focal adhesion kinase
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
Insulin Signalling
|
Reactome
|
Stimuli-sensing channels
|
GP1b-IX-V activation signalling
|
CREB phosphorylation through the activation of Ras
|
CD209 (DC-SIGN) signaling
|
RAF activation
|
MAP2K and MAPK activation
|
Negative feedback regulation of MAPK pathway
|
Negative regulation of MAPK pathway
|
WikiPathways
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
TCR Signaling Pathway
|
Senescence and Autophagy in Cancer
|
EPO Receptor Signaling
|
Regulation of Actin Cytoskeleton
|
IL-2 Signaling Pathway
|
Insulin Signaling
|
EGF/EGFR Signaling Pathway
|
MAPK Cascade
|
MAPK Signaling Pathway
|
TGF beta Signaling Pathway
|
Signaling of Hepatocyte Growth Factor Receptor
|
Kit receptor signaling pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
IL-3 Signaling Pathway
|
Cardiac Hypertrophic Response
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
RAF/MAP kinase cascade
|
Iron uptake and transport
|
Nanoparticle-mediated activation of receptor signaling
|
PDGF Pathway
|
Retinoblastoma (RB) in Cancer
|
BDNF signaling pathway
|
Integrated Pancreatic Cancer Pathway
|
Oncostatin M Signaling Pathway
|
Corticotropin-releasing hormone
|
Interleukin-11 Signaling Pathway
|
AGE/RAGE pathway
|
TNF alpha Signaling Pathway
|
B Cell Receptor Signaling Pathway
|
Prostate Cancer
|
Signaling Pathways in Glioblastoma
|
Endothelin Pathways
|
TWEAK Signaling Pathway
|
FSH signaling pathway
|
Leptin signaling pathway
|
Rap1 signalling
|
Integrin-mediated Cell Adhesion
|
GP1b-IX-V activation signalling
|
MicroRNAs in cardiomyocyte hypertrophy
|
IL-5 Signaling Pathway
|
References |
REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). |
---|
REF 2 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. |
---|
REF 3 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). |